Molecular mechanisms of transdifferentiation
转分化的分子机制
基本信息
- 批准号:7496173
- 负责人:
- 金额:$ 15.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-10 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAntibodiesAntigensAutologousB-LymphocytesBone MarrowCause of DeathCell AgingCell LineCell LineageCell Surface ProteinsCell membraneCell surfaceCellsCharacteristicsCoculture TechniquesComplementComplement Factor BDNADNA Sequence RearrangementDataDetectionDiabetes MellitusDiseaseEnsureEnvironmentEnzyme GeneEnzymesErinaceidaeEventExhibitsExposure toFutureGenesGreen Fluorescent ProteinsHandHeart DiseasesIGH@ gene clusterImmunoglobulinsIndividualIntermediate FilamentsKeratinKineticsLabelLigandsLymphocyteMediatingMembraneMesenchymalMolecularMonitorMusMutationNumbersOrganPersonal SatisfactionPhenotypePolymerase Chain ReactionPopulationProcessProteinsProto-Oncogene Protein c-kitSkinStagingStem cellsStromal CellsTestingTimeTissuesV(D)J Recombinationadult stem cellcell agecell typeclinically significantcytokineembryonic stem cellepidermis cellkeratin 14, K14keratin 5keratinocytenotch proteinpaired box 5 protein (B-cell lineage specific activator)panaceaprotein Breceptorrecombinaseresponsetissue regenerationtranscription factortransdifferentiation
项目摘要
DESCRIPTION (provided by applicant): Transdifferentiation has become a common claim for somatic stem cells, yet how this is accomplished has not been well investigated. Although much evidence exists that somatic stem cells can change their protein phenotype, it is not clear what mechanisms are involved, and whether the stem cells actually change their function and maintain this change. To investigate the mechanisms of transdifferentiation, we propose to use two cell types with distinct characteristics and functions: the epidermal stem cell (EpiSC) and the B lymphocyte. EpiSCs express the intermediate filaments keratins 5 and 14 and form sheets of cells connected by adherens and desmosomal junctions. B lymphocytes, in contrast, do not express keratin intermediate filaments. They express a defined set of cell surface proteins with well-studied kinetics of expression. In order for a B lymphocyte to produce a specific immunoglobulin, it must incur a permanent genetic change. This involves deletion and rearrangement of VDJ segments in their immunoglobulin heavy chain locus. This rearrangement is mediated by the RAG1 and RAG2 recombinase enzymes, and by the Pax5-encoded transcription factor BSAP (B cell specific activator protein). EpiSCs do not exhibit VDJ rearrangement; express the RAG1, RAG2, or Pax5 gene; or produce immunoglobulin. Our preliminary data suggest that EpiSCs can be directed to express the B lymphocyte cell markers and genes, and show rearrangement of VDJ segments. We hypothesize that EpiSCs are developmentally flexible, i.e. that they can be directed to produce cells of alternate lineages. To test this hypothesis, in Aim 1, we propose to direct EpiSCs (marked with 2gal) to transdifferentiate into B lymphocytes. We will verify that individual EpiSCs did transdifferentiate by detection of B cell surface markers and recombinase enzyme genes, and by PCR analysis for VDJ rearrangement in 2gal-expressing cells. Since permanency of the transdifferentiation event is important for future therapy, we will test whether or not EpiSCs that alter their cell lineage remain transdifferentiated when removed from the B cell inductive environment. In Aim 2, we will attempt to determine the mechanism(s) by which individual EpiSCs transdifferentiate. Our preliminary findings indicate that EpiSCs require direct contact with the S17 stromal cells in order to transdifferentiate. We hypothesize that S17 cells induce EpiSCs to alter their lineage via receptor- ligand interaction(s). We will test this hypothesis by examining the membranes of EpiSCs, before and during co-culture with S17 cells, for the expression of candidate receptor-ligand pairs. Since the skin is the largest organ with potentially the greatest number of stem cells, understanding the mechanism behind transdifferentiation of these cells is a step toward their use in tissue regeneration. Many diseases, including diabetes, Alzheimer's, and heart disease, are caused by the death of cells in major organs. To treat these diseases, the lost cells must be replaced, ideally with autologous cells. Such cells will have to be induced to change their lineage and engraft into a new environment, a process collectively called transdifferentiation. Stem cells from the epidermis, the outer layer of the skin, offer advantages over other types of adult stem cells in that they can be isolated with little harm to the individual and, since the skin is the largest organ in the body, they are present in large quantities. Therefore, determining the mechanism behind transdifferentiating epidermal stem cells and their potential for tissue regeneration has clinical significance.
描述(由申请人提供):转分化已成为体细胞的共同主张,但是如何完成这项工作并未得到很好的研究。尽管有很多证据表明体细胞可以改变其蛋白质表型,但尚不清楚涉及哪些机制,以及干细胞是否真正改变其功能并维持这种变化。为了研究转分化的机制,我们建议使用具有不同特征和功能的两种细胞类型:表皮干细胞(EPISC)和B淋巴细胞。 Episcs表达了中间丝角蛋白5和14,以及由粘附和脱染色体连接连接的细胞表。相反,B淋巴细胞不表达角蛋白中间丝。他们表达了一组定义的细胞表面蛋白,具有精心研究的表达动力学。为了使B淋巴细胞产生特定的免疫球蛋白,它必须产生永久性的遗传变化。这涉及VDJ段在其免疫球蛋白重链基因座中的删除和重排。该重排是由RAG1和RAG2重组酶以及PAX5编码的转录因子BSAP(B细胞特异性激活蛋白)介导的。 EPISC不表现出VDJ重排;表达RAG1,RAG2或PAX5基因;或产生免疫球蛋白。我们的初步数据表明,可以指示EPISC表达B淋巴细胞标记和基因,并显示VDJ段的重排。我们假设EPISC在发展上是柔性的,即可以将它们引向产生替代谱系的细胞。为了检验这一假设,在AIM 1中,我们建议将EPISC(标记为2GAL)转分解为B淋巴细胞。我们将通过检测B细胞表面标记和重组酶基因的检测以及通过PCR分析进行2GAL表达细胞的VDJ重排来验证,通过检测B细胞表面标记和重组酶基因的转变。由于转分化事件的永久性对于将来的治疗很重要,因此我们将测试改变其细胞谱系的EPISC是否在从B细胞电感环境中删除时仍会转变。在AIM 2中,我们将尝试确定单个Episc跨分散物的机制。我们的初步发现表明,EPISC需要与S17基质细胞直接接触才能转分解。我们假设S17细胞通过受体相互作用(S)诱导EPISC改变其谱系。我们将通过研究与S17细胞共培养之前和期间的Episcs的膜来检验这一假设,以表达候选受体配体对的表达。由于皮肤是最大的器官,可能是干细胞数量最多的最大器官,因此了解这些细胞转分化的机制是迈向组织再生的一步。许多疾病,包括糖尿病,阿尔茨海默氏症和心脏病,都是由主要器官细胞死亡引起的。为了治疗这些疾病,必须用自体细胞代替丢失的细胞。这些细胞必须被诱导改变其谱系并植入一个新环境,这一过程统称为转分化。来自表皮的干细胞(皮肤的外层)具有比其他类型的成年干细胞的优点,因为它们可以隔离而不会对个体造成伤害,并且由于皮肤是体内最大的器官,因此它们大量存在。因此,确定转分化表皮干细胞的机制及其组织再生的潜力具有临床意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JACKIE R BICKENBACH其他文献
JACKIE R BICKENBACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JACKIE R BICKENBACH', 18)}}的其他基金
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
8197353 - 财政年份:2009
- 资助金额:
$ 15.8万 - 项目类别:
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
7996059 - 财政年份:2009
- 资助金额:
$ 15.8万 - 项目类别:
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
7577192 - 财政年份:2009
- 资助金额:
$ 15.8万 - 项目类别:
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
7754673 - 财政年份:2009
- 资助金额:
$ 15.8万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
6496987 - 财政年份:2002
- 资助金额:
$ 15.8万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
7035837 - 财政年份:2002
- 资助金额:
$ 15.8万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
6627846 - 财政年份:2002
- 资助金额:
$ 15.8万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
6734215 - 财政年份:2002
- 资助金额:
$ 15.8万 - 项目类别:
相似国自然基金
I型干扰素通路在抗MDA5抗体阳性皮肌炎相关间质性肺疾病中的作用和机制研究
- 批准号:82302020
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
缺氧通过HIF1α/TXNDC5通路调控IgG4相关性疾病B细胞分化及抗体类别转换重组
- 批准号:82302028
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
吲哚丙烯酸对MOG抗体相关疾病小胶质细胞激活和神经炎症的调控及临床意义
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
神经胶质细胞抗体相关疾病对利妥昔单抗反应的差异性及其机制探究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
神经胶质细胞抗体相关疾病对利妥昔单抗反应的差异性及其机制探究
- 批准号:82271375
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
相似海外基金
Project 3: 3-D Molecular Atlas of cerebral amyloid angiopathy in the aging brain with and without co-pathology
项目 3:有或没有共同病理的衰老大脑中脑淀粉样血管病的 3-D 分子图谱
- 批准号:
10555899 - 财政年份:2023
- 资助金额:
$ 15.8万 - 项目类别:
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
- 批准号:
10660332 - 财政年份:2023
- 资助金额:
$ 15.8万 - 项目类别:
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function
阿尔茨海默病和唐氏综合症中 APP 拷贝数变异对 Reelin 表达和功能的影响
- 批准号:
10760161 - 财政年份:2023
- 资助金额:
$ 15.8万 - 项目类别:
The convergence of stress and sex on Abeta and tau metabolism and pathology
压力和性对 Abeta 和 tau 代谢及病理学的影响
- 批准号:
10734280 - 财政年份:2023
- 资助金额:
$ 15.8万 - 项目类别:
Evaluating a novel, orally-active TREM2-targeting drug in AD
评估一种新型口服活性 TREM2 靶向药物治疗 AD 的效果
- 批准号:
10735206 - 财政年份:2023
- 资助金额:
$ 15.8万 - 项目类别: